1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Gilead's Filing Plans For Magrolimab Depend On Further Data

Company Presents Encouraging Phase Ib Data In TP53-Mutant AML At ASH

 
• By Alaric DeArment

Regardless of future filing based on Phase Ib data, Gilead plugs along with development in TP53-mutant AML, MDS and other cancers.

Leukemia
Gilead presents magrolimab data in acute myeloid leukemia at ASH. • Source: Shutterstock

Updated Phase Ib data on Gilead Sciences, Inc.’ magrolimab in frontline acute myeloid leukemia (AML) have opened the possibility of a filing in a poor-prognosis subset of the disease, though that depends a lot on how the data turn out as they mature and the study enrolls more patients. Regardless, the company is moving ahead on plans to test the drug in a Phase III study in that same subset that will open in early 2021.

The CD47-targeting monoclonal antibody was the centerpiece of Gilead’s $4.9bn acquisition of developer Forty-Seven, which Gilead saw as having “pipeline-in-a-product” potential given the potential application in different tumor types and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from R&D

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.